MEI Pharma Inc is focused on the clinical development of novel therapies for cancer. The company's clinical drug candidate includes Pracinostat, an orally available histone deacetylase inhibitor for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Its clinical development portfolio also includes Zandelisib, an oral inhibitor of phosphatidylinositide 3-kinase delta for the treatment of patients with recurrent chronic lymphocytic leukemia or follicular non-Hodgkin's lymphoma; and ME-344, an isoflavone-based mitochondrial inhibitor for the treatment of HER2-negative breast cancer and Pracinostat, an oral histone deacetylase inhibitor. Geographically, all the business activities function through the region of the United States.

MEI Pharma, Inc.

Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company's pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue; Parvysmelanotide (VLRX001), which provoke prolonged cellular activity; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide. Clinuvel Pharmaceuticals Limited has a collaboration agreement with HK Winhealth Pharma Group Co. Limited t to treat EPP patients with SCENESSE under a named patient program in the People's Republic of China. The company was founded in 1987 and is headquartered in Melbourne, Australia.

Clinuvel Pharmaceuticals Limited

MEI Pharma develops novel and differentiated cancer therapies intended to overcome known drug resistance mechanisms in combination with standard-of-care therapies to provide improved outcomes to patients.

Metric
Company Name	MEI Pharma, Inc.	Clinuvel Pharmaceuticals Limited
Symbol	MEIP	CUV
MSH ID	COM:MEIPHARMA	COM:CLINUVEL
Market	STOCKS	STOCKS
Sector	Healthcare	Healthcare
Industry	Biotechnology	Biotechnology
Country	US	AU
Stage
Employee Count	28	16
Website	meipharma.com	clinuvel.com
LinkedIn
Founders

Metric
Market Cap	18.52M	485.02M
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue	65.30M	57.52M
Revenue (LTM)
Revenue (NTM)
Gross Profit	65.30M	50.94M
EBITDA	14.54M	36.71M
Operating Income	14.54M	35.96M
Net Income	17.78M	23.25M
EPS	2.67	0.46
Diluted EPS	2.67	0.45
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.99	0.76
Operating Profit Margin	0.34	0.53
EBITDA Margin	0.22	0.64
Net Profit Margin	0.39	0.41
Return on Equity	0.48	0.19
Return on Assets	0.43	0.15
Return on Capital Employed	0.44	0.22

COM:MEIPHARMA

MEI Pharma

Last Close

2.81

22/11 21:00

Market Cap

18.52M

Beta: -

Volume Today

12.47K

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	0.69	26.62
P/B Ratio	0.36	4.95
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	0.36	10.72
EV Multiple	1.05	22.57

Metric
Days Sales Outstanding		103.53
Days Payables Outstanding		135.48
Days Inventory Outstanding		188.05
Operating Cycle		297.33
Cash Conversion Cycle	-262.44	255.83
Asset Turnover	1.58	0.38

Metric
Operating Cash Flow	-50.47M	24.17M
Free Cash Flow	-50.48M	20.53M
Cash Flow to Debt		118.80
Operating Cash Flow/Sales	-0.66	0.52
Free Cash Flow Yield	-1.92	0.05

Metric
Cash & Equivalents	3.71M	119.94M
Accounts Receivable		-2.62M
Inventory		6.93M
Goodwill
Debt to Capitalization	0.19	0.01
Debt to Assets	0.12	0.01
Current Ratio	10.32	7.44
Quick Ratio	7.40	8.39

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	0.02	0.11
R&D to Revenue	0.35	0.02
SG&A to Revenue	0.31	0.02